Market Update (NYSE:BAX): Baxter’s Investigational 20% Subcutaneous Immunoglobulin Treatment Meets Efficacy and Tolerability Endpoints in Phase 2/3 Study
October 30, 2014 at 09:00 AM EDT
[Business Wire] – Baxter International Inc. presented the results of a Phase 2/3 study of its investigational 20 percent concentration subcutaneous immunoglobulin treatment for primary im Read more on this. Baxter International . . . → Read More: Market Update (NYSE:BAX): Baxter’s Investigational 20% Subcutaneous Immunoglobulin Treatment Meets Efficacy and Tolerability Endpoints in Phase 2/3 Study Similar Articles: Company Update: Baxter International Inc (NYSE:BAX) – Baxter’s Third Quarter Financial Results Exceed Guidance Stock Update: Baxter International Inc (NYSE:BAX) – Baxter to Present at Morgan Stanley Global Healthcare Conference Stock Update (NYSE:ABBV): AbbVie files New Drug Submission to Health Canada for its investigational, all-oral, interferon-free therapy for the treatment of hepatitis C